Gene fusion targeted therapy
US8759301B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2011 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | Mar 3, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.